Ann: Update on BLA for Graft Versus Host Disease, page-205

The serial baiter here calling MSB out for 'thuggery'. You mean in not wanting to do an RCT given the deaths in the control arm? That thuggery?

"The resubmission also included a post-hoc propensity matched study showing 6 month survival was 67% with remestemcel-L vs 10% with other unapproved therapies in highest-risk patients as identified using the Mount Sinai Acute GVHD International Consortium (MAGIC)."

Yep, pure thuggery, wanting to not be involved in the swift death of say 33 patients on a 50 patient control arm in an RCT.

Perhaps your touching concern for the FDA, so nastily picked on by MSB, might be better served for the patients dying.